{
    "2019-09-10": [
        [
            {
                "time": "2019-09-08",
                "original_text": "复星医药（02196.HK）：复宏汉霖已向香港联交所呈交经更新聆讯后资料集",
                "features": {
                    "keywords": [
                        "复星医药",
                        "复宏汉霖",
                        "香港联交所",
                        "聆讯后资料集"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2019-09-08",
                "original_text": "华鑫证券：医药生物板块业绩增长稳健 配置价值显著",
                "features": {
                    "keywords": [
                        "华鑫证券",
                        "医药生物",
                        "业绩增长",
                        "配置价值"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-09-08",
                "original_text": "复星医药（02196.HK）：复宏汉霖拟为汉霖制药不超1.7亿元融资提供担保 大额借贷担保",
                "features": {
                    "keywords": [
                        "复星医药",
                        "复宏汉霖",
                        "汉霖制药",
                        "融资",
                        "担保"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2019-09-08",
                "original_text": "仿制药一致性评价势在必行，又有多家药企品种过评",
                "features": {
                    "keywords": [
                        "仿制药",
                        "一致性评价",
                        "药企",
                        "过评"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-09-08",
                "original_text": "港股早知道：九月红包行情进行中 概念股继续飞舞",
                "features": {
                    "keywords": [
                        "港股",
                        "九月红包",
                        "行情",
                        "概念股"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "综合"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-09-08",
                "original_text": "【山证医药】医药行业周报（20190908）：建议持续关注医保目录谈判与“4+7”带量采购扩面",
                "features": {
                    "keywords": [
                        "山证医药",
                        "医保目录",
                        "4+7",
                        "带量采购",
                        "扩面"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}